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Most used abbreviations
AF: amniotic fluid
AFS: amniotic fluid stem
BM: bone marrow
BMP: bone morphogenetic protein
ES: embryonic stem
EG: embryonic germ
FGF: fibroblast growth factor
GFP: green fluorescence protein
GR: genital ridge
HSA: human α-skeletal actin
iPS: induced pluripotent stem
ICM: inner cells mass
LIF: leukemya inhibitory factor
MEF: mouse embryonic fibroblast 
PB: piggy bac
pt: post tranplantation
SCF: stem cell factor
SMA: spinal muscolar atrophy
TA: Tibialis Anteriour 
TNAP: tissue non speficic alkaline phosphatase
VPA: valproic acid
WT: wild type
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I. Riassunto
Introduzione: Le cellule staminali hanno la capacità di dare orgine ad una progenie
di cellule mature mantendo la capacità di autorinnovamento. Possono essere distinte
sulla base delle loro potenzialità in totipotenti, pluripotenti, multipotenti, oligopotenti e
unipotenti. Possono anche essere distinte in cellule staminali embrionali, fetali e
adulte. Le cellule staminali embrionali, ottenute dalla massa cellulare interna della
blastocisti, sono pluripotenti. Nell'embrione le cellule primordiali germinali danno orig-
ine ai gameti, ed esprimono i marcatori di pluripotenza (Oct4, Nanog, Sox2), ma non
sono pluripotenti. Esse possono essere riprogrammate in vitro, diventando così cel-
lule germinali embrionali. Tra le cellule staminali fetali ci sono le cellule staminali del
liquido amniotico (AFS). Queste cellule sono isolate dal liquido amniotico per la posi-
tività al marcatore c-kit e sono presenti sia nell'uomo che nel topo, anche se la loro
origine embrionale non è nota. Le cellule AFS umane sono multipotenti in vitro; le
cellule AFS umane e murine hanno uno specifico potenziale ematopoietico, in vivo e
in vitro. Recentemente è stato dimostrato che le cellule AFS umane ottenute dal pri-
mo e dal secondo trimestre di gravidanza, possono essere riprogrammate in vitro in
cellule pluripotenti, a seguito dell'aggiunta di acido valproico. Inoltre, le cellule del liq-
uido amniotico sono state anche utilizzate da diversi gruppi di ricerca per ottenere
cellule staminali indotte alla pluripotenza (iPS). Per questi motivi, le AFS rappresen-
tano una sorgente innovativa di cellule per approcci di medicina rigenerativa. L'atrofia
spinale muscolare (SMA) è una malattia autosomica recessiva, causata della
delezione o mutazione omozigote del gene della sopravvivvenza del motoneurone 1
(SMN1). Il trapianto di midollo osseo in un modello murino di SMA attenua il fenotipo
miopatico, tuttavia non lo recupera totalmente e non mostra alcun effetto benefico a
lungo termine.
Scopo della tesi: Gli scopi di questa tesi consistono nella caratterizazzione delle
cellule murine AFS isolate a fresco, nella valutaione del loro potenziale miogenico
dopo il trapianto in animali HSA-Cre, SmnF7/F7, nello studio della loro origine embrio-
nale e nell'induzione alla pluripotenza usando un metodo non virale (PiggyBac, PB).
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Materiali e Metodi: Le cellule murine AFS sono state ottenute attraverso amniocen-
tesi e successiva immunoselezione per il marcatore c-kit mediante biglie magnetiche.
Le cellule AFS sono state analizzate per l'espressione di diversi marcatori (CD90,
CD45, CD44, CD34, CD31, Flk1, Sca1, CD105) attraverso la citometria a flusso e
per l'espressione di Oct4, Sox2, c-Myc, Klf4, Nanog e Sca-1, attraverso qRT-PCR , a
diversi stadi embrionali. Sono stati valutati il potenziale ematopoietico in vitro e la ca-
pacità di formare teratomi in topi Rag2-/-γc-/-. Per la riprogrammazione a cellule embri-
onali germinali, le cellule AFS sono state seminate su feeder layer di STO o Sl4-
m220, mitoticamente inattivato, con il terreno per le cellule primordiali germinali, sup-
plementato con LIF e il fattore per la crescita dei fibroblasti (bFGF) e successi-
vamente con il terreno N2B27 2iLIF. Per il trattamento dei topi HSA-Cre, SmnF7/F7 le
cellule AFS isolate da topi GFP+, sia isolate a fresco che coltivate, sono state iniet-
tate nelle vena della coda e i topi sono stati sacrificati un mese dopo trapianto ed i
muscoli analizzati mediante ematossilina ed eosina, tricromica di Masson e con im-
munofluorescenza per l'espressione di distrofina/GFP. Per studiare l'origine embrio-
nale delle cellule AFS sono stati utilizzati due modelli murini: Oct4-GFP e TNAP-Cre.
Per l'induzione alla pluripotenza, cellule ottenute dai feti Oct4-GFP son state trasfet-
tate con i plasmidi del trasposone PB-TET contenente quattro geni (Oct4, Sox2, c-
Myc e Klf4) sotto il controllo trascrizionale del promotore inducibile tetO2 tetraciclina/
doxiciclina. L'espressione dei geni della pluripotenta è stata indotta con la doxiciclina.
Le cellule iPS così ottenute sono state testate per l'espressione dei marcatori Nanog,
SSEA-1 e per la positività alla fosfatasi alcalina.
Risultati: Le cellule AFS c-kit+ murine variano in numero durante il corso della ges-
tazione. Queste cellule esprimono i marcatori ematopoietici (CD45, CD34, Sca1),
mesenchimali (CD90, CD105) insieme a Flk1, CD31, CD44. Sulla base dell'epres-
sione di c-kit sono state identificate due popolazione cellulari: c-kithigh e c-kitlow, che
mostrano anche una differente espressione dei marcatori sopracitati. Le cellule c-kit-
low sono presenti in numero maggiore e durante il corso della gestazione diminuis-
cono mentre le c-kithigh aumentano. Entrambe le popolazioni hanno un potenziale
ematopoieitco in vitro. Le cellule murine AFS esprimono a bassi livelli i geni Oct4 e
Sox2 e ad alti livelli c-Myc e Klf4, ma la loro espressione cambia durante il corso del-
la gestazione. La stessa analisi eseguita a livello di singola cellula ha mostrato che
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allo stadio E13.5 il 5% delle cellule co-esprime Oct4, Sox2 e Klf4. Le cellule AFS
murine non formano teratoma. Negli esperimenti di terapia cellulare topi HSA-Cre,
SmnF7/F7 non trattati, morivano all'età di 10 mesi mentre topi trattati con le cellule AFS
o cellule da midollo osseo non frazionato avevano una sopravvivvenza del 75% e del
50%, rispettivamente. I topi trattati con le cellule AFS, mostravano un recuperano
della forza muscolare rispetto agli animali non trattati (+75%). I muscoli degli animali
trattati con le cellule AFS mostravano una morfologia normale con un numero basso
di fibre rigeneranti (<1%) e una normale espressione delle distrofina che per il
37.86% (± 9.48%) era GFP+. A 15 mesi dal trattamento, gli animali trattati con cellule
del midollo osseo avevano un maggior numero di fibre centro nucleate e una consis-
tente infiltrazione di tessuto interstiziale e nessuna fibra GFP+. Gli animali trattati con
le cellule AFS mostravano un fenotipo migliore e il 58.00% (± 2.43%) delle fibre mus-
colari era GFP+. Risultati simili sono stati ottenuti trattando topi HSA-Cre, SmnF7/F7
con cellule AFS espanse in vitro. 
Per cercare di differenziare le cellule AFS in cellule embrionali germinali pluripotenti
abbiamo testato due protocolli ma nessuna colonia che ricordasse cellule embrionali
germinali si è formata in vitro. Le cellule AFS isolate dai feti Oct4-GFP erano GFP
negative. Il modello TNAP-Cre è risultato essere aspecifico, perchè TNAP non
risultava essere espresso solo nelle cellule germinali primordiali. Negli esperimenti di
riprogrammazione, alcuni cloni di iPS hanno mostrato di essere doxiciclina indipen-
denti, esprimevano il gene Oct4 endogeno ed erano positivi per i marcatori Nanog e
SSEA1 e per la fosfatasi alcalina.
Discussione: Le cellule murine AFS sono una popolazione eterogenea, le cui carat-
teristiche variano durante il corso della gestazione ed esprimono marcatori
ematopoietici, mesenchimali e anche marcatori tipici delle cellule endoteliali. Il poten-
ziale differenziativo delle due popolazioni c-kithigh e c-kitlow dovrà essere testato in
vivo. L'analisi dell'espressione genica a livello di popolazione e a livello di singola cel-
lula per i marcatori della pluripotenza ha confermato l'eterogeneità delle cellule AFS.
Il trattamento degli animali HSA-Cre, SmnF7/F7 ha mostrato un potenziale miogenico
delle cellule murine AFS, anche a lungo termine, suggerendo un interessante poten-
ziale terapeutico. Le cellule AFS potrebbero contribuire a generare nuove fibre mus-
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colari fondendosi con fibre esistenti o integrarsi nelle nicchia delle cellule staminali
muscolari, ma maggiori esperimenti saranno necessari per valutare la validità
dell'ipotesi. Anche le cellue AFS coltivate hanno dimostrato il mantenimento delle
proprietà rigenerative. Questo studio suggerisce che le cellule AFS murine proba-
bilmente non derivano da cellule primordiali germinali. Tuttavia è importante ricordare
che il modello murino Oct4-GFP non è un modello di lineage tracking. Maggiori es-
perimenti saranno necessari per confermare questi risultati e per identificare l'origine
delle cellule AFS. Le cellule iPS sono un promettente strumento di ricerca come
modello di malattia o nella speranza di ottenere una sorgente di cellule per terapia.
Qui è stato dimostrato come il sistema del PB può essere un valido metodo per la
riprogrammazione delle cellule murine AFS. Questi sono solo risultati preliminari e
maggiori esperimenti saranno necessari per completarne la caratterizzazione.
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II. Abstract
Introduction: Stem cells are defined by their ability to proliferate for a long period of
time, a property known as ‘self-renewal’, and to give rise to differentiated cells. Stem
cells can be distinguished into totipotent, pluripotent, multipotent, oligopotent and
unipotent. They can also be classified into embryonic, adult and fetal stem cells. Em-
bryonic stem (ES) cells are obtained from inner cell mass (ICM) of blastocyst and are
puripotent. Primordial germ cells (PGC) in the embryo give rise to gametes but they
are not pluripotent, albeit they express Oct4, Nanog and Sox2. They can be repro-
grammed in vitro, becoming pluripotent embryonic germ (EG) cells. Amniotic fluid
stem (AFS) cells are fetal stem cells that can be isolated from the amniotic fluid (AF)
by the expression of the marker c-kit, both in human and mouse, but their origin is
unknown. Human AFS are multipotent in vitro, while both human and mouse AFS
have hematopoitic potential, in vitro and in vivo. Recently it has been demonstrated
that human AFS from first and second thrimester can be reprogrammend into pluripo-
tent cells in vitro, after supplementation with Valproic Acid (VPA). Cells from the AF
have also been used to obtain induced pluripotent stem (iPS) cells. For all these rea-
sons AFS cells seems to be a promising sources of cells for regenerative medicine.
Spinal muscular atrophy (SMA) is an autosomal recessive disease, caused by an ho-
mozygous deletion or mutation of the motor neuron 1 (SMN1) gene. Bone marrow
(BM) transplantation in a murine model of SMA attenuates the myopathic phenotype
without a full recovery and without long-term therapeutic effects.
Aims of the thesis: Characterisation of fresh mouse AFS cells, evaluation of their
myogenic potential into a model of SMA (HSA-Cre, SmnF7/F7 mouse) investigation of
their putative PGC origin and induction to pluripotency through a non-viral method
(PiggyBac, PB).
Materials and Methods: Mouse AFS cells were obtained by amniocentesis and se-
lected as c-kit+ cells with magnetic beads. Freshly isolated-AFS cells were analized
for the expression of different markers (CD90, CD45, CD44, CD34, CD31, Flk1,
Sca1, CD105) by flow citometry and the expression of Oct4, Sox2, c-Myc, Klf4 and
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Sca-1 by qRT-PCR at different embryonic stages. Hematopoitic potential was evalu-
ated in vitro, while the teratoma assay was performed in Rag2-/-γc-/- mice. For the re-
programming into EG cells cells were seeded into a feeder layer of mitotically inacti-
vated STO or Sl4-m220, in a PGC medium supplemented with LIF and basic
fibroblast growth factor (bFGF) and in N2B27 2iLIF medium. For the treatment of
HSA-Cre, SmnF7/F7 mice, GFP+ cells were injected via the tail vain and sacrificed one
month after transplantation. Tibialis Anteriour (TA) muscles were stained with hema-
toxylin and eosin, Masson’s trichrome and analized by immunofluorescence for posi-
tivity for GFP/dystrophin. The experiments for the origin of AFS have been conducted
using two mouse models: Oct4-GFP and TNAP-Cre. For the induction to pluripotency
cells were obtanied from Oct4-GFP positive embryos, and transfected with the PB-
TET transposon plasmid containing four genes (Oct-4, Sox-2, c-Myc and Klf4) under
the transcriptional control of the tetO2 tetracycline/doxycycline inducible promoter.
The expression of pluripotency gene was induced with doxycycline. iPS cells ob-
tained were tested for the expression of Nanog, SSEA-1 and for positivity to alkaline
phosphatase.
Results: Mouse AFS number chaged during the course of gestation. These cells ex-
pressed hematopoietic markers (CD45, CD34, Sca1), mesenchymal markers (CD90,
CD105) together with Flk1, CD31 and CD44. On the basis of c-kit expression two
populations were defined: c-kithigh and c-kitlow which showed differential expression of
the aforementioned markers. c-kitlow are the more abundant, but during the course of
gestation they decreases in numbers while the number of c-kithigh cells increases.
Both populations had hematopoietic potential vitro. Gene expression analysis
showed that mouse AFS cells expressed at low levels Oct4 and Sox2 and high levels
c-Myc and Klf4, and their expression changed during the course of gestation. Single
cell PCR showed that at E13.5 there 5% of cells co-expressed Oct4, Sox2 and Klf4.
Mouse AFS cells didn't form teratoma. In the cell therapy experiments HSA-Cre,
SmnF7/F7 control mice died at the age of 10 months, while mice treated with GFP+
AFS or bone marrow (BM) cells had a survival rates increased by 75% and 50% re-
spectively. HSA-Cre, SmnF7/F7 mice treated with AFS cells recovered more than 75%
of force compared to the untreated animals. One month after transplantation, mus-
cles from AFS-treated mice displayed very low number of regenerating myofibers
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(<1%) and normal dystrophin expression; moreover, 37.86% (± 9.48%) of the fibers
were GFP+. 15 months after transplantation BM-treated mice displayed a high num-
ber of central nucleated fibers and consistent infiltration of interstitial tissue and no
GFP+ myofibers, while AFS-treated mice had a mild-phenotype, close to wild-type
mice, and 58.00% (± 2.43%) of the myofibers were GFP+. Similar results were ob-
tained with HSA-Cre, SmnF7/F7 treated with mouse AFS cells expanded in culture.
To evaluate if mouse AFS cells were PGC cells, they were cultivated following the
protocol established to obtain pluripotent EG cells from PGC cells. Two different cul-
ture protocols were used, but no EG cells were obtained. AFS cells isolated from
Oct4-GFP fetuses at different embryonic stages showed no presence of Oct4+ cells.
The TNAP-Cre line resulted to be unspecific. iPS clones obtained transfecting mouse
AFS cells were doxycycline indipendent, they expressed Oct4, they were positive for
Nanog and SSEA1, and for the alkaline phosphatase.
Discussion: Mouse AFS cells are an heterogenous population, and their phenotype
changed during the course of gestation. They expressed mesenchymal, hematopietic
and endothelial markers. The two populations (c-kithigh and c-kitlow) should be tested in
vivo to asses their differentiative potential. Gene expression analysis at population
and single cells level confirmed the heterogeinity of mouse AFS cells. AFS showed a
myogenic potential, even after long-term transplantion, suggesting an interesting
therapeutic potential of these cells. AFS could contribute to the formation of new my-
ofibers by fusing with existing ones or after integration within the stem cell niche of
the muscle. The study of their origin suggested that mouse AFS cells aren't PGC.
However it is important to remind that the Oct4-GFP mouse is not a lineage-tracking
model; therefore more experiments are needed to confirm these results and to find
the origin of these cells. iPS cells are a promising research tool to obtain a model of
several diseases or as a source of cells for therapeutic approaches. Here it has been
shown that the PB system is a suitable method for the reprogramming of mouse AFS
cells. These are only preliminary results and more experiments will be necessary to
complete the characterisation of these cells. 
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III. Introduction
1. Stem cells
Stem cells are cells present in all multicellular organisms and maintain tissue home-
ostasis by replacing terminally differentiated, aged or injured cells. Stem cells are de-
fined by their ability to proliferate for a long period of time, a property known as ‘self-
renewal’, and to give rise to differentiated cells. Typically, stem cells generate inter-
mediate cell types, called precursor/progenitor both in adult e fetal tissues, before
they achieve a fully differentiated state [1]. Stem cells can be divided in different
groups on the basis of their potency or plasticity: 1) Totipotent stem cells: able to
constitute an entire organism. (i.e. the zygote, from which the embryo and extraem-
bryonic structures origin); 2) Pluripotent stem cells: able to form all the body’s cell lin-
eages, including germ cells .(i.e. embryonic stem cells); 3) Multipotent stem cells:
form multiple cell lineages that constitute an entire tissue. (i.e.: haematopoietic stem
cells); 4) Oligopotent stem cells: able to form two or more lineages within a tissue.
(i.e:. neural stem cells can create a subset of different neurons in the brain); 5)
Unipotent stem cells: form a single lineage. (i.e.: spermatogonial stem cells). 
Stem cells can be also classified on the basis of their origin in a) embryonic, b) adult
and c) fetal stem cells. 
(a) Embryonic Stem Cells
To date stem cell lines that have been derived from the embryo are the i) embryonic
stem (ES) cells [2,3] ii) embryonic germ (EG) cells [4] and epiblast stem cells (EpiSC)
[5,6]. (Figure 1)
13
Figure 1: Developmental origins of pluripotent stem Cells. Different types of pluripotent
cells can be derived by explanting cells at various stages of early embryonic development.
Modified from [7]
(i) ES cells
The first ES cells were successfully derived directly from mouse blastocysts in 1981;
when inner cells mass (ICM) cells were put in particular culture condition, they
proliferated in the form of mouse ES cells [2,3]. These cells are pluripotent, in fact
when injected into a host blastocyst they are able to repopulate an embryo (forming
chimera embryo) and to contribute descendents to all tissues of the adult, including
the germline [8,9]. Mouse ES cells can be maintained in vitro using a medium
containing fetal bovine serum (FBS) and leukaemia inhibitory factor (LIF), with the
addition of a mouse embryonic fibroblast (MEF) feeder layer [2]. Recently, it has
been shown that mouse ES cells can self-renew in basal medium if autocrine
mitogen-activated protein kinase (MAPK) signalling is blunted and glycogen synthase
kinase 3 (GSK-3) activity is reduced [10]. The two inhibitor (2i)-culture system,
supplemented with LIF, allows efficient derivation and expansion of germline-
competent ES cells from different strains of mice, including 129, CBA and NOD
[9,10], and, for the first time, from the rat [11,12]. Markers that are used to
characterized mouse ES cells are: Alkaline phosphatase [13], Oct4 [14], Sox2 [15],
Nanog [16,17] and SSEA1 [18].
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(ii) EG cells and Primordial Germ cells 
The generation of mouse embryonal carcinoma (EC) cells from teratocarcinomas that
arose spontaneously in male gonads [19] prompted speculation that it may be possi-
ble to derive pluripotent stem cell lines directly from primordial germ cells (PGC). In
the embryo PGC are cells that gave rise to gametes. During mouse embryo develop-
ment germ cells undergo through a series of changes, that bring them to maruration.
Different phases are distinguishable (Figure 2): 1) Specification: Specification of PGC
is initiated through signals provided by the extraembryonic ectoderm (ExE), and the
visceral endoderm (VE) that surrounds the epiblast cells and instructs a small num-
ber of epiblast cells to become PGCs [20]. Both the ExE and VE are the sources of
bone morphogenetic protein (BMP) 4, 8b, and 2 which are required for the acquisition
of competence in PGC precursors [21]. Specification start around E5.5 and it finished
at E8.0, during this phase PGCs express different markers, Blimp-1, Fragilis, Stella,
Nanos3, Prdm14 plus mesodermal genes including T, Fgf8, and Snail become re-
pressed, whereas pluripotency-associated genes such as Sox2, Oct4, Nanog are up-
regulated. PGCs are also recognizable for the activity of the alkaline phosphatase
[22,23]. After specification, the germ cells become transcriptionally silent at E8.5 and
are subjected to an extensive reprogramming of their genomes.[24] 2) Migration:
From around E7.5, PGCs start to migrate to the hindgut, then toward the mesentery
and finally they reach genital ridges (GRs), which they colonize by E10.5 to initiate
sexually dimorphic development [23] (Figure 2). During their migration and early peri-
od in the GRs, PGCs undergo active proliferation [25]. However, at E13.5, both male
and female germ-cell growth is arrested, and female germ cells immediately enter
prophase of the first meiotic division [26], while male germ cells are arrested and en-
ter the G0 phase of the cell cycle until birth, when prospermatogonia resume mitosis
[27].
Figure 2: Specification and migration of mouse primordial germ cells. (A) A schematic of
germ cell specification and migration in developing mouse embryos. PGC precursors (E6.25)
and PGCs are shown as green circles in embryos from E6.25 to E12.5, and the direction of
migration is denoted by a green arrow. The timing of expression of key genes (Blimp1,
Prdm14 and Stella) and alkaline-phosphastase activity is shown below. (B) Signalling activi-
ties for PGC specification at E5.5-E5.75 and at E6.25. (C)  A view of PGC migration from the
hindgut through the mesentery to genital ridges at E9.0-E10.5. The direction of PGC migra-
tion is denoted by a green arrow and anterior is towards the top. Al, allantois; AVE, anterior
visceral endoderm; DE, distal endoderm; DVE, distal visceral endoderm; EM, embryonic
mesoderm; Epi, epiblast; ExE, extra-embryonic ectoderm; ExM, extra-embryonic mesoderm;
PGCs, primordial germ cells; Sm, somite; VE, visceral endoderm. Modified from [23].
Despite the expression of the pluripotent stem cells markers (like Oct4, Nanog and
Sox2) PGCs are unipotent, they can differentiate only into sperm or eggs, and if in-
jected into an host blastocyst, they don't contribute to chimeras [28,29]. Pluripotency
is achieved by culturing the posterior region of E8.5 mouse embryos, or GRs at
E10.5 on feeder cells in the presence of particular cytokines, like LIF, steel factor/
stem cells factor (SCF), basic fibroblast growth factor (bFGF) and serum [4]. Pluripo-
tent cell obtained with this method are called EG cells and they closely resemble ES
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cells [30]. FGF appears not to be necessary if PGCs are cultured directly in 2i medi-
um with LIF [31]. EG cells can be obtained also from explanted GRs at E11.5 and
E12.5, but by this stage, the developing germ cells have undergone imprinting
erasure, which renders the derivative EG cells less able to integrate into chimaeras,
and particularly into the germline. [32]. Derivation of human cells with features of EG
cells has also been reported [33,34]. However, although these cultures express
pluripotency marker genes and demonstrate broad differentiation, undifferentiated
cells have not been clonally propagated or maintained during long-term culture yet
[35]. Thus, whether the ability to reprogram to pluripotent stem cells in vitro is a phe-
nomenon specific to mice or is a general property of mammalian PGCs remains an
open question.[31]
 (b) Adult Stem Cells
Adult stem cells are capable of maintaining, generating, and replacing terminally dif-
ferentiated cells within their own specific tissue as a consequence of physiologic cell
turnover or tissue damage due to injury. Adult stem cells are rare: within the bone
marrow (BM), for example, truly hematopoietic stem cell (HSC) are less than the
0.01% [36]. Furthermore, adult stem cells are dispersed in tissues and behave very
differently, depending on their environment. For example, HSCs are constantly re-
newed in the bone marrow where they differentiate into mature types of blood cells
[37]. On the contrary stem cells in the small intestine are stationary, and are physical-
ly separated from the mature cell types they generate [38]. Adult stem cells can be
found in different tissues like brain, dental pulp, muscle, bone marrow, skin, intestine
and pancreas and have been extensively characterized also for a therapeutic ex-
ploitation. Different studies have shown that blood stem cells (derived from meso-
derm) may be able to generate both skeletal muscle (also derived from mesoderm)
[39] and neurons (derived from ectoderm) [40], however the “plasticity” of adult so-
matic stem cells is still controversial, and in general, existing evidence suggests that
in vivo such unexpected transformations are exceedingly rare.[41] 
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(c)  Fetal Stem Cells
Fetal stem cells (FSCs) can be found in fetal tissues such as blood, liver, bone mar-
row, pancreas, spleen and kidney, and stem cells are also found in cord blood and
extraembryonic tissues such as amniotic fluid, placenta and amnion. Their primitive
properties, expansion potential and lack of tumorogenicity make them an attractive
option for regenerative medicine in cell therapy and tissue engineering approaches.
[42]
(i) Amniotic Fluid Stem Cells
In humans, the AF generates at the beginning of the second week of gestation as a
small film of liquid between the cells of the epiblast [43]. The fluid expands separating
the epiblast (the future embryo) from the amnioblasts (the future amnion), thus
forming the amniotic cavity [44]. The origin of amniotic fluid cells is still debated
[45,46] but, it is known that the majority of cells within the amniotic fluid are terminally
differentiated and have limited proliferative capacity [47,48]. Different studies have
demonstrated the presence of a subset of cells with a proliferative and differentiation
potential also in the AF [49], these include cells found in mid-gestation expressing the
haematopoietic marker CD34 [50] as well as cells with mesenchymal features
(MSCs), able to proliferate in vitro more rapidly than mesenchymal fetal and adult
cells [51,52,53,54,55,56,57]. Amniotic fluid MSCs are negative for hematopoietic
markers such as CD45, CD34 and CD14 [54,55,56,57,58]. Despite their high prolifer-
ation rate, these cells display a normal karyotype when expanded in vitro and do not
form tumours in vivo [52]. They exhibit a broad differentiation potential towards mes-
enchymal lineages [54,55,59,60,61]. De Coppi et al. isolated c-kit-positive (CD117)
cells that represent about 1% of cells present in second-trimester amniotic fluid.
These cells were named amniotic fluid stem (AFS) cells. They can be cultured with-
out feeders, double in 36h, are not tumorigenic, have long telomeres and retain a
normal karyotype for over 250 population doublings [62]. Cultured human AFS cells
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are positive for ES cell (e.g. Oct-4, Nanog and SSEA-4) and mesenchymal cell mark-
ers such as CD90, CD105 (SH2), CD73 (SH3/4) and several adhesion molecules
(e.g. CD29 and CD44) [62,63]. Furthermore, it was possible to generate clonal
human lines from these cells, verified by retroviral marking, which were capable of
differentiating into lineages representative of all three embryonic germ layers. Almost
all clonal AFS cell lines express Oct-4 and Nanog, markers of a pluripotency [62]. c-
kit+ lineage- cells from human and mouse amniotic fluid display a multi-lineage
haematopoietic potential in vitro and in vivo [64]. The potentiality of AFS cells have
been tested in various models of diseases, it has been demostrated that they con-
tribute to lung [65], kidney [66], cardiac [67], bone [68], and smooth muscle regenera-
tion [69,70]. Moschidou et al. showed that human c-kit+ cells of first and mid-trimester
can be fully reprogrammed to pluripotency by culture on Matrigel in human embryon-
ic stem (hES) cell medium supplemented with the histone deacetylase inhibitor
(HDACi) valproic acid (VPA). The reprogrammed cells share 82% transcriptome
identity with hES cells and are capable of forming embryod bodies (EBs) in vitro and
teratomas in vivo. After long-term expansion, they maintain genetic stability, protein
level expression of key pluripotency factors, high cell-division kinetics, telomerase ac-
tivity, repression of X-inactivation, and capacity to differentiate into lineages of the
three germ layers, such as definitive endoderm, hepatocytes, bone, fat, cartilage,
neurons, and oligodendrocytes. [71,72]                        
2. Induced Pluripotent Stem Cells                                                      
In 2006 Takashashi and Yamanaka found that the ectopic expression of defined
factors into a somatic cell could reprogram differentiated cell into a pluripotent cell,
that was called induced pluripotent stem (iPS) cell. They screened a pool of 24
pluripotency-associated candidate genes, coexpressed with retroviral vectors in
mouse fibroblasts which had a dormant drug resistance allele integrated into the
ESC-specific Fbxo15 locus. The combination of 24 factors activated Fbxo15 and
induced the formation of drug-resistant colonies with characteristic ES cells
morphology [73]. Successive rounds of elimination of individual factors then led to the
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identification of the minimally required core set of four genes: Klf4, Sox2, c-Myc, and
Oct4. iPSCs generated by selection for Fbxo15 activation expressed markers of
pluripotent stem cells such as SSEA-1 and Nanog, generated teratomas when
injected subcutaneously into immunocompromised mice, and contributed to different
tissues of developing embryos when injected into blastocyst [73]. However, these
‘‘first-generation’’ iPSCs were only partially reprogrammed, in fact they expressed
lower levels of several key pluripotency genes compared with ES cells, showed
incomplete promoter demethylation of ES cell regulators such as Oct4, and failed to
generate postnatal chimeras or contribute to the germline. Different laboratories
improved the iPS cells generated for example using the selection for Nanog or Oct4
instead of Fbxo15 [74,75,76]. Recently, rare iPSC lines have been identified that are
even capable of generating ‘‘all-iPSC’’ mice upon injection into tetraploid blastocysts
[77,78][79,80]. iPSCs have also been derived from a number of different species,
including humans [81,82,83], rats [84], and rhesus monkeys [85] and from other
somatic cells beyod fibroblasts, such as keratinocytes [86,87], neural cells [88,89],
stomach and liver cells [90], and melanocytes [91], as well as from genetically
labeled pancreatic β cells [92] and terminally differentiated lymphocytes [88,93].
Different groups have also used amniotic fluid cells as source for obtain iPS cells.
These works are summarized in the table below.
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Cellls Factors Method of delivery References
human and mouse
amniotic fluid de-
rived cells (the last
one selected for c-
kit and not selected)
Oct4, Sox2, c-Myc,
klf4 (also only klf4
and c-Myc for
mouse cells)
retroviral vector [94]
human amniotic flu-
id derived cells from
β-thalassemia
patient
Oct4, Sox2, c-Myc,
Klf4
lentiviral vector
(doxycycline-
inducible )
[95]
human amniotic flu-
id-derived cells 
Oct4, Sox2, c-Myc,
Klf4
retroviral vector [96]
human amniotic flu-
id-derived cells 
Oct4, Klf4 retroviral vector [97]
human amniotic flu-
id derived cells from
trisomy 21 patient
Oct4, Sox2, c-Myc,
Klf4
lentiviral vector [98]
human amniotic flu-
id-derived cells 
Oct4, Sox2, c-Myc,
Klf4
retroviral vector [99]
human amniotic flu-
id derived cells from
β-thalassemia
patient
Oct4 and Sox2 or
Oct4, Sox2, and
Klf4 
retroviral vector [100]
human amniotic flu-
id-derived cells
Oct4, Sox2, c-Myc,
Klf4
bacteriophage
ΦC31 integrase
[101]
human amniotic flu-
id-derived cells
CD34+
Oct4 retroviral vector [102]
human amniotic flu-
id-derived cells
Oct4, Sox2, c-Myc,
Klf4
retroviral vector [103]
human amniotic flu-
id-derived cells
Oct4, Sox2, c-Myc,
Klf4
retroviral vector [104]
Table 1: iPS obtained from human/mouse amniotic fluid stem cells.
21
(a) Factor delivery into target cells
(i) Viral delivery methods
In 2006 Takahashi et al., used constitutively active retroviral vectors that stably inte-
grated into the host cell genome to introduce c-Myc, Klf4, Oct4, and Sox2 into the so-
matic cells [105]. Even if retroviral transgenes are usually silenced toward the end of
reprogramming [106], this process is often incomplete, resulting in partially repro-
grammed cell lines that continue to depend on exogenous factor expression and fail
to activate the corresponding endogenous genes [73,107,108]. In addition, residual
activity or reactivation of viral transgenes in iPS cell-derived somatic cells can inter-
fere with their developmental potential [73] and frequently leads to the formation of
tumors in chimeric animals [75]. Lentiviral vectors are also used to produce iPS cells,
but they are are even less efficiently silenced in pluripotent cells than retroviral vec-
tors [109,110]. The use of inducible lentiviral vectors, whose expression can be con-
trolled by the inert drug doxycycline, diminishes the risk of continued transgene ex-
pression and allows for the selection of fully reprogrammed iPS cells, since cells that
depend on exogenous factor expression readily stop proliferating upon doxycycline
withdrawal [106,109]. Lentiviral vectors are also more efficient than retroviral vectors
at infecting different somatic cell types and can be used to express polycistronic cas-
settes encoding all four reprogramming factors, thus increasing reprogramming effi-
ciency [110,111]. To summarize the integrating methods to reprogramm somatic cells
into iPS cells have adavantages to have the highest efficiency and in the case of
lentiviral vector, to transduce dividing and non dividing cells, on the other hand they
integrate into the genoma of cells, with an incomplete proviral silencing and with the
risk of insertional mutagenesis and tumor incidence. 
(ii) Integration-free iPSCs
Approaches to derive iPS cells free of transgenic sequences are aimed at circum-
venting the potentially harmful effects of leaky transgene expression and insertional
mutagenesis. This is relevant when considering iPS cells technology in a therapeutic
setting. Techniques to generate integration-free iPS cells can be subdivided into
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three categories: (1) those that use vectors that do not integrate into the host cell
genome, like for example adenoviruses and plasmids, (2) those that use integrating
vectors that can be subsequently removed from the genome, like for examples trans-
posons and loxP-flanked lentiviruses, and (3) those that do not use DNA-based vec-
tors at all, such as Sendai virus, proteins, modified mRNA and microRNA. The first
integration-free iPSCs were generated from adult mouse hepatocytes using noninte-
grating adenoviral vectors [112], and from MEFs transfected with plasmids [75].
These experiments provided the proof of principle that transient expression of the
four classical reprogramming factors is indeed sufficient to induce pluripotency in so-
matic cells. Human fibroblasts have also been reprogrammed into iPSCs with aden-
oviral vectors [113] and Sendai virus [114], as well as with polycistronic minicircle
vectors [115] and self-replicating selectable episomes [116], albeit the latter system
required the simultaneous overexpression of additional factors, including another po-
tent oncogene (Oct4, Sox2, c-Myc, and Klf4, together with Nanog, Lin28, and
SV40LT). Reprogramming efficiencies with current non-integrating methods are sev-
eral orders of magnitude lower (0.001%) than those achieved with integrating vectors
(0.1%–1%), most likely because factor expression is not maintained for a sufficient
length of time to allow complete epigenetic remodeling. To avoid this issue, several
laboratories have developed integration-dependent gene delivery vectors with incor-
porated loxP sites that can be subsequently excised from the host genome by tran-
sient expression of Cre recombinase [117,118]. This approach enables the efficient
generation of iPSCs from different cell types, especially if polycistronic vectors are
used [110,119]. Transgene-free iPSCs can also be generated with PB transposons,
mobile genetic elements that can be introduced into and removed from the host
genome by transient expression of transposase [120,121]. Successful reprogram-
ming has been achieved recently without the use of viral or plasmid vectors at all.
Specifically, iPSCs have been derived from both mouse and human fibroblasts by
delivering the reprogramming factors as purified recombinant proteins [79] or as
whole-cell extracts isolated from either ESCs [122] or genetically engineered
HEK293 cells [123]. While the use of purified proteins represents an attractive ap-
proach for the generation of transgene-free iPSCs, its efficiency is extremely low and,
in the recombinant protein approach, required the addition of VPA to the culture me-
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dia. A more efficient and safer way of producing integration-free iPSCs may be the
introduction of modified RNA molecules encoding for the reprogramming factors into
somatic cells [124]. To improve the overall low efficiencies of generating iPSCs with
most non-integrating approaches, screens for chemical compounds that promote re-
programming have been performed. This led to the identification of a number of mol-
ecules that significantly increase reprogramming efficiencies in the context of Oct4,
Klf4, Sox2, and c-Myc overexpression [125,126]. Notably, some of these molecules
can also replace individual reprogramming factors, raising the possiblility of deriving
iPSCs solely with chemicals [125,126]. To summarize the integration-free methods to
obtain iPS cells have the advantages to avoid the genomic integration, but they have
a low efficiency.
(b) Identification of iPSC colonies  
It is really important the selection of successfully reprogrammed clones from partially
reprogrammed or simply transformed iPS colonies. The reactivation of endogenous
pluripotency-associated genes such as Fbxo15 [73], Nanog or Oct4 [74,75,76], and
Utf1 [127] linked to drug selection cassettes has been successfully employed for this
purpose. A general limitation of any drug selection approach is that it requires genetic
engineering of cells or mice. To circumvent this problem, lentiviral vector systems
have been developed that carry promoter fragments of pluripotency genes whose ac-
tivity can be selected for, and that, in principle, can be applied to a wide range of
murine and human cell types [128]. For human iPS cells, expression of surface mark-
ers such as TRA-1-81 has been shown to enrich for reprogrammed cells [129]. A
more stringent approach to identify faithfully reprogrammed human iPSCs without the
use of drug selection combines the detection of surface markers with that of ‘‘indica-
tor retroviruses’’ expressing fluorescent proteins, which become silenced upon acqui-
sition of pluripotency [130]. Importantly, high-quality iPSCs can be derived from un-
modified somatic cells without drug selection or fluorescent reporters at all by simply
using morphological criteria [74,131,132], although this approach requires careful
characterization of the resultant cell lines. This ‘‘no selection’’ approach is therefore
most powerful when combined with doxycycline-inducible vectors, as cells that have
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entered a self-sustaining pluripotent state can be easily selected by removal of doxy-
cycline [106,109], even though, in rare cases, doxycycline-independent partially re-
programmed cells have been reported [107]. 
(c) Therapeutic potential of iPSCs
The generation of patient-specific stem cells has been a long-standing goal in the
field of regenerative medicine. This point has been reached thank to discovery of iPS
cells. iPS cells have a lot of potentiality in fact they provide a unique platform from
which to gain mechanistic insight into a variety of diseases, to carry out in vitro drug
screening, to evaluate potential therapeutics and to explore gene repair coupled with
cell-replacement therapy (Figure 3). Experiments in mice suggest that the treatment
of genetic disorders with iPS cells is feasible: Jaenisch and colleagues [133] showed
that iPSCs can be used to rescue the defects seen in an animal model of sickle cell
anemia, in another study mice transplanted with heterologous, iPSC-derived en-
dothelial progenitor cells corrected a phenotype of hemophilia A [134]. The study and
treatment of many degenerative diseases, such as type I diabetes, Alzheimer’s dis-
ease, and Parkinson’s disease, is limited by the accessibility of the affected tissues,
as well as the inability to grow the relevant cell types in culture for extended periods
of time. The idea behind so-called ‘‘disease modeling’’ is to derive iPSCs from pa-
tients’ skin cells and then differentiate them in vitro into the desired cell types, there-
by recapitulating the disease in a cell culture dish. The advantage of this approach
over currently used strategies is that the very cell type that is compromised can be
recreated in culture to be studied, even when the cell type is long gone from the pa-
tient. Moreover, because iPSCs grow indefinitely in culture, they provide an unlimited
source for any desired specialized cells. Ultimately, the goal of this approach is to
use create models of disease as a platform to identify novel drugs. Several laborato-
ries have already derived iPSCs from patients suffering from Huntington’s and
Parkinson’s disease, ALS, juvenile diabetes, muscular dystrophy, Fanconi anemia,
Down syndrome, and others pathologies [118,135,136,137], moreover, three reports
showed that iPSCs derived from patients suffering from the disorders SMA [138], fa-
milial dysautonomia (FD) [139], and LEOPARD syndrome [140] recapitulated cell ab-
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normalities in vitro as seen in patients. Remarkably, when the cultured cells were ex-
posed to experimental drugs for these diseases, the ‘‘symptoms’’ were partially
alleviated in culture. 
Figure 3: Medical applications of iPS cells. Reprogramming technology and iPS cells have
the potential to be used to model and treat human disease. Modified from [141]
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3. Spinal muscular atrophy
SMA is one of the most frequent genetic causes of death in childhood. It is an auto-
somal recessive disease that, after muscular dystrophy, is the most common neuro-
muscular disease. In its most severe form, disease onset occurs before 6 months of
age with death of respiratory distress usually within 2 years. The major pathological
characteristic of SMA is selective degeneration of lower α motor neurons in the ven-
tral horn of the spinal cord, resulting in progressive muscle denervation, skeletal
muscular atrophy, particularly of the proximal muscles, and eventual paralysis. SMA
is caused by homozygous deletion or mutation of the ubiquitously expressed survival
of motor neuron 1 (SMN1) gene, and the most frequent mutation is a homozygous
deletion of SMN1 exon 7 [142]. In humans, there are two SMN genes, the telomeric
SMN1 and its centromeric homolog SMN2, caused by the intrachromosomal duplica-
tion of 5q13. Crucially, SMN2 differs from SMN1 at base pair position 840, resulting
in a C to T substitution that excludes exon 7 from approximately 85–90% of SMN2
transcripts [143]. Protein product lacking exon 7 is not functional and is rapidly de-
graded; therefore, the SMN2 gene produces considerably less SMN protein than the
SMN1 gene. SMN is an essential cellular protein and homozygous deletion is not tol-
erated [144]. SMA is the consequence of variable, but low, levels of SMN produced
from the SMN2 locus. The variation is due to copy number variation, and SMA dis-
ease severity correlates with SMN2 copy number [145]. SMN is an ubiquitously ex-
pressed protein of 294 AA that forms a large multiprotein complex both in the cyto-
plasm and in the nucleus where it is concentrated in a structure called “gems”
(gemini of coiled bodies) [146]. SMN is involved in and facilitates cytoplasmic assem-
bly of small nuclear ribonucleoprotein into the spliceosome, a large RNA-protein
complex that catalyzes the splicing reaction. In the nucleus, SMN appears to be di-
rectly involved in pre-mRNA splicing, transcription, and metabolism of ribosomal RNA
[147,148]. In order to test the hypothesis that AFS cells could functionally engraft in a
diseased muscle, a mouse model of SMA, in which the phenotypic disease is full
blown in muscle tissue, has been used [149]. In this model, the murine Smn exon 7 is
flanked by two LoxP sequences (SmnF7) and deletion is occurring only in skeletal my-
ofibers by placing the Cre recombinase under the control of the human α-skeletal
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actin gene promoter (HSA-Cre). Similarly to other models of muscle disease, HSA-
Cre SmnF7/F7 mice display a high proportion of myofibers with central nuclei, which
lead to muscle fibers necrosis over time, heterogeneous myofiber diameters, and
signs of interstitial infiltrate [149]. In contrast to the mdx mouse model, HSA-Cre
SmnF7/F7 animals manifest kyphosis, progressive muscle weakness, shrinkage, and
subsequent respiratory arrest, similarly to the clinical features exhibited by the mdx/
mTR mouse model [150]. Therefore, the overall survival of HSA-Cre, SmnF7/F7 ani-
mals is estimated to be of 10 months. After BM transplantation, the myopathic phe-
notype attenuates and the myofibers number and motor performance normalize up to
9 months of age [151]. However, the engraftment of BM cells in the diseased muscle
tissue is poor: the cells are not able to rescue the phenotype and make a substantial,
long-term therapeutic contribution [151]. 
4. c-kit and Stem Cell Factor
Steel factor (also known as stem cell factor, kit ligand or mast cell growth factor) is
the product of the Steel locus and a member of the short-chain helical cytokine fami-
ly. It has been shown by many studies to be an essential survival factor for PGC
[152,153,154,155]. There are two forms of Steel protein, generated by alternative
splicing: soluble Steel factor and membrane-bound Steel factor. The membrane-
bound form lacks an extracellular domain containing a proteolytic cleavage site,
which normally causes release of the extracellular region of the protein [156,157].
The receptor for Steel factor is the product of the W locus, c-kit, a tyrosine-kinase re-
ceptor of the PDGFRB superfamily [158,159,160]. The kit receptor tyrosine kinase
(RTK) is centrally involved in the development of multiple cell lineages, including
hematopoietic and germ cells, melanocytes, and the interstitial cells of Cajal (ICC)
[161,162,163,164]. Insights into the roles of this receptor and its cognate ligand in
these developmental processes have been greatly facilitated by the large series of
naturally occurring mutations in the murine genes that encode these molecules, the
dominant white spotting (W) and steel (Sl) loci, respectively. Thus, mice with loss-of-
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functions in either the W or Sl loci are anemic and exhibit white spotting on the fur,
sterility, and a concomitant loss of the ICC and intestinal pacemaker activity.[165]
5. Mouse amnion formation
The amnion is the innermost extraembryonic membrane that surrounds the fetus of
amniotes and delineates the fluid-filled amniotic cavity, thereby providing a confined
environment within the conceptus and conferring protection and shock resistance. In
most amniotes, the amnion is a thin and avascular transparent membrane. In human,
both amnion and chorion surround the embryo and both membranes fuse during the
second trimester of pregnancy, while the yolk sac remains rudimentary [166]. In con-
trast, in mouse, the chorion will never fuse with the amniotic membrane after the
physical separation of the amniochorionic fold shortly after gastrulation at E7.0 [167].
The chorion becomes incorporated in the chorionic disk of the placenta, whilst the
amnion becomes surrounded by the visceral yolk sac, except in the part of the chori-
onic disk. Importantly, amnion on the one hand and yolk sac and chorionic disk on
the other hand remain spaced by the fluid-filled exocoelomic cavity (Figure 4). In
mouse embryos, the amnion consists throughout gestation of a simple bilayered
membrane of squamous mesoderm and ectoderm, which face the exocoelomic and
amniotic cavity, respectively. In the mouse embryo the epiblast gives rise to the em-
bryo proper, as well as the amniotic ectoderm and the extraembryonic mesoderm of
chorion, amnion, visceral yolk sac and allantois, respectively [168]
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Figure 4: Schematic representation of a mouse embryo illustrating the position of the
extraembryonic tissues before and after axial rotation. During the process of axial rota-
tion the embryo becomes enwrapped in its extraembryonic membranes. Extraembryonic
mesoderm is shown in red; yellow represents amniotic ectoderm and embryonic ectoderm
(embryonic mesoderm is not depicted); green represents trophectoderm-derived extraembry-
onic lineages; blue shows extraembryonic endoderm. Modified from [169]
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IV. Aim
Different groups have shown the potentiality of human AFS cells, but little is known
regarding the mouse counterpart. The aims of this thesis are the following:
• to characterise mouse AFS cells freshly isolated;
As tool for studying the biological properties of the cells and use them in regenerative
medicine field, we will perform cytofluorimetric analysis of amniotic fluid from fetuses
of a wide window of gestational ages.
• to evaluate the myogenic potential of mouse AFS after transplantation in a mouse
model of SMA, HSA-Cre, SmnF7/F7;
To explore the therapeutic efficiency of murine AFS cells. A well established model of
muscle disease will be used as pre-clinical model: a muscle mutant of SMA (HSA-
Cre,SmnF7/F7) where skeletal muscle is the direct damaged tissue.
• to investigate their PGC origin;
In the past, different groups identified in genetically modified mice three systems in-
fluenced by the absence of c-kit: 1) PGC, 2) neural crest cells and 3) HSC [165]. In
particular the attention will be done on the hypothesis that mouse AFS could be PGC
that during the migration go through the amniotic fluid. This hypothesis has been
based on data obtained with human AFS; it has been demonstrated that human AFS
cells, obtained from AF of the first-trimester of gestation, express PGC markers
(FRAGILIS, SSEA1, TNAP, NANOS, BLIMP1, PUM2, STELLA, DAZL, and VASA),
and have the ability to reprogram to pluripotency by culture on Matrigel in human ES
Medium supplemented with the histone deacetylase inhibitor (HDACi) valproic acid
(VPA) [71].
• to induce the pluripotency using a non-viral method (PiggyBac, PB).
The technique of obtaining iPS really represent a new avenue for using pluripotent
stem cells and a non-viral method will be tested to reprogram mouse AFS cells, using
the PB system.
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V. Materials and Methods
1. Mice
Male mice and female mice of the diffent models (C57BL6/J, HSA-Cre SmnF7/F7,
C57BL6/GFP, TNAP/Cre, Oct4-GFP, Z/Red, Z/eGFP and Tomato) used were mated
to obtain the fetuses from which the amniotic fluid has been obtained. All procedures
were approved by the University of Padua/Toronto’s Animal Care and Use Commit-
tee and, in accordance with Italian and Canadian law, were communicated to the
Ministry of Health and local authorities.
2. Amniotic fluid collection and stem cell selection
Embryo age was defined relative to the morning of vaginal plug discovery (E0.5). All
dissections were performed under a stereomicroscope (Leica Microsystems). Amni-
otic fluid samples were harvested from pregnant mice between embryonic days from
E10.5 to E16.5. Amniocentesis has been done following an accurate procedure: first
there is the removal of the maternal uterine wall, to expose the yolk sac. At this point
the chorion and yolk sac are carefully removed. Amnion rupture result in amniotic flu-
id leakage, and amniotic fluid is harvested with a syringe fitted with a 28-gauge nee-
dle. Murine amniotic fluid-derived c-kit+ cells were isolated using the Miltenyi Mouse
Lineage Cell depletion kit and the CD117 MicroBeads kit (all from Miltenyi Biotech). 
3. Flow cytometry analisys
Flow cytometry was performed using a FACSCalibur flow cytometer (BD Bio-
sciences) with CellQuest acquisition software (BD Biosciences) or a Gallios flow cy-
tometer (Beckman Coulter). The antibodies used were CD177 APC (Biolegend) or
CD117 PE Cy5 (eBioscience), Sca1 FITC, CD90 FITC, CD44 FITC, CD34 PE and
CD105 PE (All from BD Biosciences), CD31 FITC, Flk1 PE, CD45 PE (all from BD
Biosciences) and the 7AAD (BD pharmingen) or DAPI as viability probe.
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4. In vitro hematopoietic differentiation protocol
Myeloid and erythroid potentials were assessed by cell culture in a semisolid medi-
um. Around 500 cells were gently mixed with 1 mL MethoCult M3434 methylcellulose
colony assay medium (StemCell Technologies) and cultured for 11 days in 24-well
plates at 37°C in humidified 5% CO2 air. Colonies consisting of at least 50 cells were
counted every week and classified according to morphology and color of the colony
and the single cells, using an inverted Olumpus IX71 microscope (10x magnification).
Pictures of colonies were taken with a Olympus Camera C3040 and processed with
analySIS software.
5. Real Time PCR
In order to quantify the different amount of Oct4, Sox2, c-Myc, Klf4, Nanog, Sca1, c-
kit and Pax7 mRNAs in freshly isolated cells or muscle samples, total RNA has been
extracted using RNeasy Plus Mini kit (QIAGEN GmbH) following the supplier’s in-
structions. RNA has been then quantified with a ND-1000 spectrophotometer and
1ug has been retrotranscripted with SuperScript II and related products (all from Invit-
rogen) in a 20 ul reaction. Real-time PCR (qRT-PCR) reactions were performed us-
ing a LightCycler II (Roche). Reactions have been carried out in triplicate using 4 ul
of FASTSTART SYBR GREEN MASTER (Roche) and 2 ul of primers mix FW plus
REV (final concentration, 300/300 nM) in a final volume of 20 ul. Serial dilutions of a
positive control sample have been used to create a standard curve for the relative
quantification. The amount of each mRNA has been normalized for the content in β2-
microglobulin. Primer sequences were the following: c-kit FW: TGGTCCGCTGCC-
CTCTGACA, c-kit REV: CCTTGATGGCTGCCCGCACT, Pax7 FW: AGCAAGCCCA-
GACAGGTGGCG, Pax7 REV: GGCACCGTGCTTCGGTCGCA, Oct4 FW: TGGAG-
GAAGCCGACAACAATGAGA, Oct4 REV: TGGCGATGTGAGTGATCTGCTGTA,
Nanog FW: CCCTTCCCTCGCCATCACACTG, Nanog REV: GGAAGGGCGAGGA-
GAGGCAGC, Sox2 FW: TCGGGGAAGCGTGTACTTAT, Sox2 RW: CATGCA-
CAACTCGGAGATCA, β2-microglobulin FW: GCTTCAGTCGTCAGCATGG, β2-mi-
croglobulin RW: CAGTTCAGTATGTTCGGCTTCC, Klf4 FW:
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TGCCCCGACTAACCGTTGGCGT, Klf4 REV: GCTGCACCAGCTCCGCCACT, c-
Myc FW: TGCCCGCGATCAGCTCTCCT, c-Myc REV:
CGTGGCTGTCTGCGGGGTTT
6. Single Cell Analisys
(a) Single cell deposition
Mouse AFS cells have been sorted for ckit using a FACS Aria I Sorter equipped with
an automatic cell deposition unit (BD Bioscience). 7-Aminoactinomycin D (BD Bio-
science) was added as a viability marker in the sorting procedure. Cells have been
collected in 96-well plates for molecular biology containing 5 µL of PBS-DEPC 0.1%,
and stored at -80°C.
(b) Single cell PCR.
Mouse AFS cells isolated as single cells were analysed using protocols described in
[170]. Primers sequences were the following: c-kit FW_A: GATCCCGACTTTGTCA-
GATG, ckit REV_B: TTTGGGACAAACGTCAGGTC, c-kit FW_C: ACACGT-
GCAGCAACAGCAAT, c-Myc FW_A: AAACTTTGCCCATTGCAGCG, c-Myc REV_B:
CCTCGTCGCAGATGAAATAG, c-Myc FW_C: TCCGGGGAGGGAATTTTTGT, Klf4
FW_A: CACCCACACTTGTGACTATG, Klf4 REV_B: TACTGAACTCTCTCTCCTGG,
Klf4 FW_C: AAATTCGCCCGCTCCGATG, Nanog FW_A: CCACAGTTTGCC-
TAGTTCTG, Nanog REV_B: GACCTTGTTCTCCTCCTCCT, Nanog FW_C: CTTA-
CAAGGGTCTGCTACTG, Oct4 FW_A: CTCTTTGGAAAGGTGTTCAG, Oct4
REV_B: CTCGAACCACATCCTTCTCT, Oct4 FW_C: TGGAGGAAGCCGACAA-
CAAT, sca1 FW_A: AGAGGGCTCCAGGAAGAATT, Sca1 REV_B: TCTGTGT-
TACTCAGGAGGCA, SCa1 FW_C: ATCCTGGGTACTAAGGTCAA, sox2 FW_A:
CATGGGCTCTGTGGTCAAGT, sox2 REV_B: CCTACTCTCCTCTTTTTGCAC, sox2
FW_C: GGGACATGATCAGCATGTAC, 28S FW_A: ACAGTGATG-
GTTCAGGAGGG, 28S REV_B: AAGTAACAGAACTTGGCTGG, 28S FW_B:
CGCTACTATGAGAAGCCTTG.
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7. Teratoma assay
For teratoma assay 105 mouse AFS cells were injected into the muscle of the
hindlimb of Rag2-/-γc-/- mice. Transverse sections (8–10 um thick) of isopentane-
frozen muscles injected were stained with hematoxylin and eosin to evaluate the
tumors presence.
8. AFS cell expansion and PGC reprogramming
For the expansion freshly isolated AFS cells were plated onto a feeder layer of mito-
mycin C-treated mouse embryonic fibroblasts SNL (applied Stem Cells Inc.) in
DMEM knockout (Invitrogen) supplemented with 15% heat-inactivated FBS (Invitro-
gen), 0.1 mM nonessential aminoacids (Invitrogen), 2 mM L-glutamine (Invitrogen),
50 U (ug)/ml penicillin/streptomycin (Invitrogen), 0.01 mM 2-mercaptoethanol (Sig-
ma), 10 ng/ml BMP4 (R&D Systems), and 20 ng/ml LIF (Sigma). Cells were cultivat-
ed at 37°C and 5% CO2. For PGC reprogramming freshly isolated AFS cells, or gen-
ital ridges obtained from embryos Oct4GFP positive at E10.5-12.5, were trypsinised
to a single cell suspension and plated onto a feeder layer of mitomycin C-treated Sl4-
m220 (from Dr. Matsui from the Cell Resource Center for Biomedical Research, Insti-
tute of Development, Aging and Cancer, Tohoku University, Japan.) in DMEM High
Glucose (Invitrogen) supplemented with 15% heat-inactivated FBS (Invitrogen), 2mM
Glutamax (Invitrogen), 50 (ug)/ml penicillin/streptomycin (Invitrogen), 0.1mM sodyum
pyruvate (Invitrogen), 0.01mM 2-mercaptoethanol (Sigma), 25 ng/ml FGF-2 (R&D
Systems) and 1000U/ml LIF (Millipore) for the first two days and for the following
days in 2iLIF medium composed of 50% DMEM F-12 (Invitrogen), 50% Neurobasal
Medium (Invitrogen), 1% Knockout Serum Replacement (Invitrogen), 2mM Glutamax
(Invitrogen), 50 (ug)/ml penicillin/streptomycin (Invitrogen), 0.01mM 2-mercap-
toethanol (Sigma), N2 (1x) and B27 (1x)1x supplement (Invitrogen), BSA Fraction V
7.5% (Invitrogen), 1000U/ml LIF (Millipore), MEK inhibitor PD0325901 (1 uM) and
GSK3 inhibitor CHIR99021 (3 uM) (both from Selleck Biochemical). 
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9. Cell Injection
Three-month-old HSA-Cre, SmnF7/F7 mice were randomized to receive either no treat-
ment, mouse BM cells, or mouse AFS cells. Approximately 25,000 GFP+/+ cells were
injected via tail vein in the AFS cells group and 50,000 GFP+/+ cells were injected via
tail vein in the BM group. In vitro expanded AFS cells were sorted with an Aria FACS
system (Becton Dickinson) and selected for the expression of GFP and c-kit prior to
injection. After sacrifice (1 month post-transplantation (pt)), muscle differentiation and
regeneration were investigated by assessing the percentage of cells derived from
donor GFP+/+ cells in recipient muscles, considering the total number of muscle fibers
(both centrally nucleated and with peripheral nuclei). 
10. Muscle physiology, histology, and
immunofluorescence analyses
In vivo determination of gastrocnemius strength and contraction kinetics was carried
out as described previously [171]. Transverse sections (8–10 um thick) of isopen-
tane-frozen skeletal muscle (Tibialis Anteriour, TA) of 3-month- old transplanted mice
were stained with hematoxylin and eosin and Masson’s trichrome. To evaluate the
total number of centrally nucleated muscle fibers, serial 40-um sections of the entire
TA muscle were prepared. Immunostaining of GFP or dystrophin was performed us-
ing rabbit anti-GFP (1:200; Invitrogen) or anti- dystrophin (1:150; Abcam). Sections
were mounted with Vecta-shield and 4,6-diamidino-2-phenylindole (Vector Laborato-
ries), observed under an Olympus BX60 microscope (Olympus), and pictures taken
using Viewfinder Lite software.
11. In Vivo imaging
Prior to imaging, mice were anesthetized (with a mixture of Rompum and Zoletil giv-
en i.p.), shaved and depilated to completely remove hair, and imaged on the eXplore
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Optix time-domain imager (ART, Montreal, Quebec). Image processing and data
analysis were performed using explore Optiview 1.04 software (ART).
12. DNA extraction and PCR analyses
DNA from organ and tissues samples was extracted with a DNeasy Blood & Tissue
kit (QIAGEN GmbH) and then quantified with a ND-1000 spectrophotometer (Thermo
Scientific). Genomic DNA samples extracted from GFP+ AFS cells and from WT or-
gans were, respectively, used as positive and negative controls for the amplification
of the GFP gene. PCR reactions for the TERT and GFP genes were carried out as
previously described [172]. Primers sequences were the following: GFP FW:
TGAACCGCATCGAGCTGAAGGG, GFP REV:TCCAGCAGGACCATGTGATCGC,
TERT FW: ACCCACTATCCTTGTGGTGCATGA, TERT
REV:AGATCGAGCAGCTGCAAGACCATA.
13. PB production 
PB expression vectors were generated using standard cloning procedures. The plas-
mid DNA for mouse AFS transfection was prepared using a QIAprep Spin Miniprep
Kit and Maxiprep Kit (Qiagen). 
14. Transfection, iPS cell generation and culture
Mouse AFS cells were expanded like described in point 7 (AFS cell expansion and
PGC reprogramming) and transfected after 7 days of culture, with the Yamanaka's
factors (Oct4, Klf4, cMyc, Sox2). Factors were in an ORFs linked with 2A peptide se-
quences, into the PB-TET transposon plasmid (called PB-TET-OKMS) under the
transcriptional control of the tetO2 tetracycline/doxycycline inducible promoter. All
was linked to the gene of a cherry fluorescent protein through an IRES sequence.
Cells were transfected with the PB-TET-OKMS transposon plasmid, in conjunction
with a PB transposase expression plasmid (mPBase) and with the reverse tetracy-
cline transactivator (rtTA) transposon plasmid. Fugene HD Transfection Reagent
(Promega) has been used, with a ratio DNA :Transfection Agent = 1ug : 4ul. The ex-
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pression of the Yamanaka's factors were induced with 1.5 ug/ml doxycycline (Sigma)
the day after the transfection. Twenty-four hours after transfection, cells were fed with
fresh ES media daily without passage. The resulting colonies were picked 30 days
after transfection and iPS clones were maintained on inactivated feeders in ES
medium.
15. Alkaline phosphatase staining and
immunfluorescence
Alkaline phosphatase staining was carried out following the manufacturer’s instruc-
tion (Vector Red Alkaline Phosphatase Substate Kit I). Immunofluorescence analyses
were performed using as primary antibodies SSEA1 (1:100, Millipore) and Nanog
(1:100, ReproCells) . Secondary antibodies were respectively Alexa564-conjugated
goat anti-mouse IgM (1:200) and Alexa594-conjugated chicken anti-rabbit IgG
(1:200) (all from Life Technologies). Primary and secondary antibody immunofluores-
cence were performed according to standard protocols. Nuclei were stained with
DAPI solution in PBS 1X (Life Technologies).
16. Statistical analysis
Values were reported as means ± SD or SE. Statistical significance of the differences
between means were assessed by analysis of variance followed by the Studen-
t−Newman−Keuls test or by Student's t−test for paired or nonpaired data. Statistical
significance wiere set at P < 0.05.
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VI. Results
1. Mouse AFS cells characterisation
Mouse amniotic fluid was collected from offspring of female GFP+/+ and males GFP-/-,
and all the analysis were performed on cells selected for the GFP expression to
avoid any maternal contamination. On the amniotic fluid collected a lineage depletion
for the hematopoitic lineage was done, to remove all the mature cells, and after that a
selection for the markers c-kit. The selection for this marker was done beacuse c-kit
have been previously identified as marker of stem cells in the human AF. [62]. Within
the lineage-negative fraction, some c-kit positive cells were detected in a variable
proportion according to the gestational age (Figure 5). 
Figure 5: Presence of mouse AFS cells in the amniotic fluid. The percentage of mouse
AFS cells as a function of the gestation stage is indicated in the left panel. The right panel
shows the total number of mouse AFS cells per embryo equivalent (EE). Means are repre-
sented by bars.
Along the period of gestation there is a peak in number of mouse AFS cells present
in the amniotic fluid at E11.5 and then they slowly drecrease. The total number of
mouse AFS cells in the mouse AF per embryo equivalent is around 10.000-20.000
cells for embryo (Figure 5, right panel). 
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Figure 6: Phenotypic characterisation of mouse AFS cells. Mouse AFS cells were stained
with antibodies specific for CD90, CD45, CD31, CD34, Flk1, Sca1, CD105 and CD44. The
histograms show the expression of the markers at different embryonic stages (from E11.5 to
E14.5, for E12.5 experiments n=3). 
An immunological phenotype was performed to characterize the mouse AFS that ex-
press markers characteristic of hematopoietic (CD45, CD34, Sca1), mesenchymal
(CD90, CD105) cells together with CD44,CD31 and Flk1, and their expression
change during the course of gestation (Figure 6). Considering the ckit+ population of
the AF CD90, a marker of the mesenchymal stem cells, was expressed from 20-25%
of ckit+ cells at E11.5-13.5 and its expression decreased to 16% at E14.5; CD45, the
marker that define the commitment to the hematopoietic lineage, was expressed by
8.5% of cells and then it increased during the gestation, reaching 40% of expression
at E14.5. CD31 (Platelet Endothelial Cell Adhesion Molecule 1, Pecam-1) is a marker
expressed by endothelial cells, and its expression in the ckit+ cells ranged from 7% to
12%. CD34 is an hematopoietic cells marker, differently expressed during the gesta-
tion since there was an expression from 5% to 8% at E11.5 and E13.5, respectively,
and an higher expression at E12.5 and E14.5 (18% and 30%). In the same way Flk1,
the receptor for vascular endothelial growth factor (VEGFR), changed during the ges-
tation, indeed it was expressed from 5% to 9% of cells at E11.5 and E13.5, while in-
creased at E12.5 and E14.5 (21% and 23%). Sca1 is a characteristic marker of HSC
and different adult stem cells, it was expressed by a low number of cells at E11.5
(around 2% of cells) and reached 20% at E14.5. CD105 is another marker of mes-
enchymal stem cells, it was expressed by 14%, 31%, 17% and 38% of the c-kit+ cells
at the different embryonic stages. CD44 is a cell surface glycoprotein involved in cell-
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cell interactions, in the AF was expressed by 12% of c-kit+ cells at E11.5, and then its
expression increased during the course of gestation. Two distinct populations have
been discoverd in the AF, they differ for the intensity of expression of ckit, as it is
shown in figure 7, and they have been called c-kithigh and c-kitlow. They can be easily
distinguished for the expression of the marker c-kit, a magnitudo of intensity that
ranged from 101 to 102 identify the ckitlow, while the c-kithigh had an intensity of expres-
sion from 102 to 104 (Figure 7A). They differed also for their presence in the AF dur-
ing the course of gestation (Figure 7B); it has been evaluated that the c-kitlow were
predominant (99%) at E11.5, while at this stage the number of c-kithigh was very low
(1%). In particular during the course of gestation the number of the c-kitlow decreased
and the one of c-kithigh increased, in fact at E16.5 c-kitlow were 60% and c-kithigh were
40%. These two subpopulations have been studied under the immunological phe-
notype (Figure 7C), and it has been shown that they differ for the expression of sev-
eral markers. Notably the two populations had an opposity phenotype regarding the
expression of markers, like CD44, CD45 and CD90. c-kithigh were negative for Flk1,
Sca1 (except for < 1% of cells positive at E14.5) and CD105 (except for 5% of cells
positive at E14.5), and there were few cells positive for CD90, CD31 and CD34. c-kit-
low were positive for all the markers evaluated in all the considered embryonic stages,
with different trends during the different days. To investigate if a different phenotype
correspond to a different functional potentiality the hematopoietic differentiation has
been studied at the embryonic stage E12.5 for the two populations. Mouse AFS cells
c-kithigh and c-kitlow were sorted and cultured in semisolid medium to assess their
hematopoietic function (Figure 8). The two populations exhibited the same clono-
genic potential (18 colonies per 500 cells, ie, 3.6%). 
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Figure 7: Characterisation of c-kithigh and c-kitlow population in the mouse amniotic fluid.
(A) mouse AFS cells were analyzed by flow cytometry and two population were distinguished
on the basis of intensity of expression of the marker c-kit. (B) c-kithigh and c-kitlow change in
number during the course of gestation. (C) Immunological phenotype on the basis of expres-
sion of different markers (CD31, CD34, CD44, CD45, CD90, CD105, Flk1 and Sca1).
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Figure 8: In vitro hematopoietic differentiation. The percentages of the different types of
colonies generated, obtained 11 days after seeding 500 candidate cells is shown. Represen-
tative images of day 11 mAFS cell–derived hematopoietic BFU-E, CFU-M, and CFU-GEMM
cells (cultured in semisolid methylcellulose-based medium supplied with hematopoietic cy-
tokines) are shown.
These colonies included erythroid colony- and burst-forming units (CFU- or BFU-E)
and granulocyte/macrophage CFUs (CFU-G/M/GM). The proportion of mixed colony-
forming unit-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM) cells
was similar in the two analyzed population , thus attesting to the presence of multipo-
tent hematopoietic progenitors (Figure 8). As mentioned before human AFS were
characterized for their expression of pluripotency markers like Oct4 and SSEA4, in
addition to their capability to differentiate into cells of the three germ lineages [62].
Mouse AFS cells were also studied for the expression of pluripotency markers Oct4,
Sox2, Nanog, c-Myc and Klf-4. Real Time-PCR analysis showed that the expression
of these markers was very low, excepted for the genes c-Myc and Klf-4 at E11.5 (Fig-
ure 9). 
c"kithigh( c"kitlow(
BFU/CFU"E( 28% 19%(
CFU"GM( 55%( 68%(
CFU"GEMM( 17%( 13%(
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Figure 9: Gene expression analisys of pluripotency markers. RT-PCR analyses were
performed to investigate the expression of pluripotency genes at two different embryonic
stages (E11.5 and E12.5). Values are expressed in arbitrary units as gene/β2microglobulin
ratio, and considering 1 the level of expression of mouse ES cells.
Quantitative gene expression analysis determine the average gene expression within
a population, overlooking possible cell-to-cell heterogeneity that could lead to differ-
ent cell behaviors or fates. Understanding individual cell behavior requires multiple
gene expression analyses of single cells, and may be fundamental for the under-
standing of all types of biological events and/or differentiation processes. To deeper
investigate the gene expression of the pluripotency markers, single-cell PCR analysis
has been performed at different embryonic stages. All the attained data are summa-
rized in the Figure 10. The single cells analysis confirmed that mouse AFS cells did
not express Nanog, as showed with the Real Time-PCR analisys at population level.
Regarding the other pluripotency markers c-Myc, Klf4 and Sox2 were expressed in
all the analyzed embryonic stages however the expression levels were not always
the same; at E10.5 the number of positive cells for c-Myc, Klf4 and Sox2 were 70%,
30% and 11% respectively, at E11.5 were 84%, 29% and 4%, at E12.5 were 16%,
87% and 13%, at E13.5 were 45%, 55% and 10%, at E14.5 were 85%, 4% and 2%.
It is worth of notice that Oct4 gene was not expressed at E10.5 and E14.5, was low
at E11.5 and E12.5 respectively 2% and 11%, while was expressed in the 76% of
cells at E13.5. Summarizing, the embryonic stage of E13.5 seems to be the best
temporal window to find mouse AFS cells expressing the pluripotency genes Oct4,
Sox2, c-Myc and Klf4 on a considerable numbers of cells (76%, 38%, 55% and 45%).
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Figure 10: Frequency of expression of plurypotent genes. Single-cell multiplex RT-PCR
analyses were performed to investigate the frequency of expression of pluripotent genes at
different embryonic stages (E10.5-E14.5). In all cases 28S was used as an endogenous con-
trol. The results are shown as histograms representing the proportion of cells expressing
each gene. Single mAFS cells were sorted and analyzed by multiplex RT-PCR, as described
in “Methods.” Each row shows the same (numbered) individual cell. Each column shows a
different gene. Empty symbols represent cells not expressing that particular mRNA; gray
symbols, positive cells where mRNA levels were not quantified.
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Also Sca-1 was expressed by a variable percentage of cells (27%, 33%, 24%, 38%
and 67%) at the different embryonic stages analyzed. Cells that co-expressed genes
at the different embryonic stages are summarized in the table below:
E10.5 E11.5 E12.5 E13.5 E14.5
ko 0% 0% 10% 43% 0%
ks 0% 0% 13% 5% 0%
km 11% 18% 8% 2% 2%
kom 0% 0% 0% 0% 0%
koms 0% 0% 0% 0% 0%
sm 7% 2% 0% 2% 2%
so 0% 0% 0% 5% 0%
om 0% 0% 0% 33% 0%
kos 0% 0% 0% 5% 0%
Table 2: Frequency of coexpression of pluripotency genes in mouse AFS cells.
A test considered the gold standard for the evaluation of the pluripotency is the ter-
atoma in vivo fomation. These tumor masses that contain differentiated derivatives of
all three embryonic germ layers, grow when pluripotent cells are injected in immuno-
compromised mice. [173]. Pluripotency of mouse AFS cells has been evaluated after
injection of about 105 cells into the muscle of the hindlimb of Rag2-/-γc-/- mice. After
six weeks from the injection, there were no presence of teratoma (data not shown).
To summarize, (1) mouse AFS cells are an heterogenous population and their char-
acteristics change during the course of gestation but they do not form teratoma, (2)
they expressed the majority of the pluripotency markers (all the Yamanaka's factor
plus Sca-1) at the embryonic stages 13.5, as evalueted by the single cells gene ex-
pression analysis, (3) they also express hematopoietic and mesenchymal stem cells
markers as shown by the flow cytometry analysis, finally (4) the cells possess
hematopoietic potential, as demostrated by the methylcellulose cell culture of the two
populations c-kithigh and c-kitlow, confirming previous data [64]. 
2. Myogenic potential of mouse AFS cells
To evaluate the myogenic potential of the mouse AFS cells a mouse model of SMA
called HSA-Cre, SmnF7/F7 has been used. As previously described in this model the
defect is localized only in the muscle, no other tissues are affected from the genetic
ablation. Three months old mice were choosen for the transplantation, because at
this time the muscle defects is evident. Mice were divided into three groups: ones
that received the tail vein trasnplantation with mouse AFS cells (25.000 cells), ones
with mouse BM cells (50.000 cells), both obtained from GFP+ donator and one with-
out transplantation (untreated). The survival of the treated mice was evaluated, mice
not treated die at the age of 10 months, while at that time mice treated with mouse
AFS or BM cells had a survival rates of 75% and 50% respectively (Figure 11 a). The
treated mice differed from the untreated animals on respect to their force, in fact gas-
trocnemius contraction kinetics was measured blinded 1-month after the transplanta-
tion and this analysis showed that both BM- and AFS-treated mice had levels of
strength comparable to the ones obtained with wild type (WT) mice (Figure 11b).
Consistently with survival and muscle strength, AFS-treated mice were similar to wild
type mice in terms of weight, movement, and skeletal anatomy as confirmed at Mi-
croCT scan analysis (Figure 11c-e). On the contrary, HSA- Cre, SmnF7/F7, which did
not receive any treatment, showed pronounced kyphosis with impaired movements
by the age of 8 months (Figure 11d). 
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Figure 11: Transplanted animals improve in survival and clinical parameter. (a) Survival
curve: AFS-treated mice increased life expectancy both when compared with BM-treated and
-untreated animals. Untreated=10 animals, BM=8 animals, AFS=8 animals (***,p < .001). (b)
Muscle strength analyzed at different frequencies. Normalized force frequency on muscle
mass displays that both BM- (n=8) and AFS-treated (n=8) mice had 75% more muscle
strength than untreated (n=6) animals 1 month after transplantation (***, p < .001). (c): Body-
weight of untreated (n=4), AFS-treated (n=4), and WT (n=8) mice at 8 months (***, p < .001).
(d): The kyphosis, which is present in the untreated mice from 3 months of age, disappeared
in AFS-treated mice. (e): MicroCT scan of skeletal anatomy of untreated and AFS-treated
mice confirmed the different curvature of the spine. Abbreviations: AFS, amniotic fluid stem;
BM, bone marrow; WT, wild type.
Following morphological muscle analyses performed 1-month pt (i.e., 4 months of
age; Figure 12a), in both BM- and AFS- treated mice, the histological aspect of the
muscle tissue resulted indistinguishable from WT, with few central nucleated fibers
(<1%, comparable to WT mice; Figure 12 a, e). In contrast, untreated animals pre-
sented a very large number of central nucleated fibers (mean value: 63.70% ±
0.41%, p < .001; Figure 12 a, e). Masson’s trichrome staining showed that untreated
animals presented large connective tissue areas between fibers, which were absent
in both WT and cell-treated mice. Immunofluorescence analyses clearly indicated
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that the morphological appearance of muscle in BM- and AFS-treated animals was
correlated with a relevant proportion of GFP+ fibers (31.57% ± 7.04% and 37.86% ±
9.48%, respectively for BM and AFS). Changes in the muscle tissue were also con-
firmed by the observed distribution of dystrophin expression, which was similar only
in transplanted and WT mice but differed in the untreated animals (Figure 12a). De-
spite the similarity between BM- and AFS-treated animals in terms of physiology and
number of central nucleated and GFP+ myofibers, the regenerative index, defined as
the number of donor-engrafted myofibers generated per 105 transplanted cells, dif-
fered significantly between BM- (1,263.00 ± 282.76) and AFS-treated mice (3,029.16
± 758.71; p < .001), respectively (Figure 12b). Additionally, RT-PCR revealed that 1
month after treatment, in the TA muscles of AFS-treated mice, there was higher ex-
pression of Pax7 than in untreated or BM-treated mice (p < .05; Figure 12c). Further
evidence of the differences between the two groups was confirmed by analysis of
surviving animals at 15 months post-transplantation (Figure 12d). Morphological
analysis of samples from BM-treated mice displayed a high number of central nucle-
ated fibers (39.90% ± 17.68%) and consistent infiltration of interstitial tissue between
the myofibers, a situation that differed greatly from the one observed in AFS-treated
mice. Moreover, at this stage (15 months pt), no GFP+ fibers were found in BM-treat-
ed animals, whereas 58.00% ± 2.43% of myofibers were GFP+ in AFS-treated mice
(Figure 12e). This finding highlights the sustained effect of AFS cells transplantation. 
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Figure 12: Restoration of muscle phenotype in mutant mice. (a): Three-month-old HSA-
Cre, SmnF7/F7 mice were transplanted alternatively with BM or AFS cells and sacrificed 1
month after treatment for analyses. One month after transplantation, hematoxylin and eosin
staining reveals a normal appearance of the TA muscle structure after receiving either BM or
AFS cells. On the contrary, TA muscle of untreated animals present fibers disarrangement
(dystrophin staining) with interstitial tissue deposition identified at Masson’s trichrome. Scale
bar=100 um. (b): Regeneration index indicates that AFS cells are more likely to participate in
muscle regeneration than BM cells;***, p < .001. (c): Quantitative real time-PCR for Pax7 ex-
pression revealed that mutant muscles receiving AFS cells (n=3) expressed higher levels of
Pax7 than untreated (n=3) and BM (n=3) animals; *, p < .05. (d): Fifteen months after trans-
plantation, histological and immunofluorescence analyses revealed a more sustained, long-
term engraftment of AFS cells, relative to BM cells. Scale bar =100 um. (e): Graphs of raw
numbers (number of fibers per area [N/A]; each letter on the x-axis is an individual muscle
evaluated in three representative high-power fields) and percentages of central nucleated
and GFP+ fibers (black) in untreated (blue), BM (red), and AFS-treated (green) mice at 1 and
15 months after transplantation; ***, p < .001. 
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Given the few number of freshly isolated AFS cells it was important to evaluate if
their myogenic potential was maintened after a cell culture expansion. After 2 weeks
of culture on a fibroblast feeder layer (Figure 13) cells grown about two folds (data
not shown). Mouse AFS cells were then sorted for the dual expression of GFP and c-
kit (89.50%±6.27) and transplanted in 3-months-old HSA-Cre, SmnF7/F7 mice. Like-
wise to what had been observed with the freshly isolated AFS cells, one month after
treatment the muscles displayed a normal phenotype: fewer than 1% of the fibres
were centrally nucleated and 21.01%±3.57 were GFP+ (Figure 13). Multiple skeletal
muscle engraftments in the transplanted animals were also confirmed by RT-PCR
analyses of GFP expression (Figure 13d). Twenty percent of the fibres were of donor
origin, a remarkable result, given that (i) some adult stem and progenitor cell popula-
tions have proven difficult to expand in culture and (ii) skeletal muscle satellite cells
multiply rapidly in culture but show diminished regenerative capacity when transplant-
ed in vivo [174]. Nevertheless, 20% was significantly lower than the value achieved in
animals having received freshly isolated cells. Further work is required to improve the
expansion culture conditions in order to better maintain their myogenic potential. In
conclusion, these data indicate that AFS cells have a myogenic potential. 
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Figure 13: Transplantation of expanded AFS cells generates skeletal muscle tissue. (a)
After 15 days of culture, AFS cells GFP+/c-kit+ were sorted and injected in HSA-Cre, SmnF7/F7
mice. GFP+ AFS cells were passaged twice on a mouse embryonic fibroblast feeder layer.
Magnification 10X and 20X. (b) Immunofluorescence with anti-GFP and anti-dystrophin anti-
bodies: 1 month after transplantation, the muscles of treated HSA-Cre, SmnF7/F7 mice dis-
played a considerable number of GFP+ fibres and a normal levels of dystrophin expression.
Scale bar=100 µm. (c) Percentage of GFP+ in cultured AFS-treated animals. (d) PCR analy-
ses of gastrocnemius, TA and diaphragm muscles isolated from mice transplanted with cul-
tured AFS cells. First lane: amplification of the GFP gene (307 bp). Second lane: amplifica-
tion of genomic TERT (132 bp) to confirm the quality of the extracted DNA. For each PCR,
the positive control (Pos Ctrl) for GFP amplification was the genomic DNA extracted from
GFP+ AFS cells; NTC=no template control.
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3. Are mouse AFS cells PGC?
Moschidou et al. demonstrated that human AFS cells obtained from the first and sec-
ond trimester can be reprogrammed in vitro when cultured under particular culture
condition. Human AFS cultivated following the above mentioned method expressed
markers typical of ES (like OCT4, SOX2, NANOG, SSEA3, SSEA4, TRA1-81,
TRA1-60) and EG cells (FRAGILIS, TNAP, NANOS, STELLA, BLIMP, VASA, DAZL),
and are able to form teratoma when injected into immunocompromised mice, and
embryod bodies in vitro, as conseguence this cells can be defined pluripotent. Simi-
larly PGC are not pluripotent per se, but following stimulation with particular cytokines
they can be reprogrammed into pluripotent EG cells.
To investigate whether mouse AFS cells could be PGC, the following procedures
have been assessed:
1. Cultivation of the cells using the same protcol established for the reprogramming
of PGC into EG cells.
2. Use of two mouse models as PGC markers.
Regarding the first point two protocols, respectively described in [28] and [31], have
been followed for the culture of mouse AFS cells. Following the first protocol, mouse
AFS cells were obtained at different embryonic stages (10.5, 11.5 and 12.5) from wild
type C57BL6/J fetuses, and seeded on a feeder layer of STO (a fibroblast cell line,
genetically modified to express the membrane-bound form of stem cell factor, SCF)
mitotically inactivated, in a medium supplemented with LIF and b-FGF. Cells were left
to growth in this condition for more than 10 days (time at which normally EG colonies
start to appear after the reprogramming of PGC). Mouse AFS cells never formed EG
colonies when cultivated in this condition, and when analyzed for the expression of
the plurypotency markers (Oct4 and Sox2) by immunofluorescence, they were nega-
tive for these markers (data not shown, n=5). This result highlighted that no repro-
gramming process was on going. The second protocol [31] has also been tested for
the reprogramming of mouse AFS. Mouse AFS cells were obtained from Oct4-GFP
fetuses (with a mixed background CD1/129) at E10.5 and E11.5. This mouse model
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gives the possibility of monitoring and identify cells GFP positive, signal of the
endogenous expression of the gene Oct4. As positive control genital ridges (GRs)
obtained from the same fetuses have been used. A feeder layer of mitotically inacti-
vated Sl4-m220 (that like STO are a fibroblast cell line, genetically modified to ex-
press the membrane-bound form of stem cell factor, SCF) has been used to seed
mouse AFS and GRs; for the first two days in culture they were feeded with PGC
medium supplemented with LIF and FGF-2, and from the third day and on with the
N2B27 2iLIF medium (experiments n=5). While the reprogramming protocol worked
for GRs seeded, in fact they formed EG colonies that were GFP positive (Figure 14),
no colonies appeared in the culture of mouse AFS cells. 
Figure 14: Mouse EG cells obtained from Oct4-GFP GRs in N2B27 2i-LIF condition.
Phase contrast and fluorescence images of Oct4-GFP EG cells obtained after 11 days in cul-
ture of PGC obtained from GRs at E11.5, cultured on a Sl4-m220 feeder layer. Scale
bar=100um.
Following the second strategy, to deeper investigate the possible PGC nature of AFS
cells two mouse models has been used: the Oct4-GFP and TNAP-Cre. The Oct4-
GFP mice is characterised by the insertion of a gene reporter, the Green Fluores-
cence Protein (GFP), into the Oct4-genomic fragment of 18kb, this encompass the
Oct-4 gene and its 5'- and 3'-flanking sequences. The transgene reproduced the
endogenous expression pattern of Oct-4 in embryos and in the germ cell lineage; so
the Oct4 expression is restricted only in the PGC from E10.5 until E13.5 (for female,
while for male germ cells the expression of endogenous Oct-4 continue even after
they are mitotically arrested), [175]
Alkaline phosphatase (AP) is one of the first marker that identifies PGC in the allan-
tois during the mouse embryo development. In the mouse model TNAP-Cre the Cre
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recombinase is knocked into the locus of the Tissue Non-Specific Alkaline Phos-
phatase, TNAP gene. In these models mouse AFS cells were isolated and analized
by flow cytometry for the expression of Oct4 and TNAP. Regarding the Oct4-GFP
model the AF was collected from pregnant females (obtained from mating of males
Oct4-GFP CD1 x females 129 or males 129 x females Oct4-GFP CD1), and ana-
lyzed to see if in the c-kit+ cells of the AF there were Oct4GFP+ cells. The AF was
collected from different embryonic stages (E10.5 experiment n=1, E11.5 experiment
n=1, E12.5 experiment s n=4, E13.5 experiment n=2) the linegage depleted cells
were incubated with c-kit antibody and a viability probe to exclude the death cells, an-
alyzed by flow cytometry. In all the samples studied there weren't signals for the
GFP, as shown in the figure 15, while the GFP signal was present in the positive con-
trol, constituted by GRs obtained from the same fetuses from which AF was collect-
ed. For each analyzed sample the threshold of GFP positivity was defined after the
comparision between GRs and AFS cells obtained from Oct4-GFP positive and neg-
ative fetuses. In figure 15 are showed results obtained only from Oct4-GFP positive
fetuses.
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Figure 15: Flow Cytometry analisys. (A) Representative Dot Plots of cells obtained from
GRs collected from Oct4-GFP+ fetuses showed that in the viable cells the expression of Oct4
is around 2% (B) mouse AF cells collected from Oct4-GFP positive fetuses were lineage de-
pleted and stained with antibody specific for c-kit markers and for the viability probe DAPI. In
all the embryonic stages analyzed, no signal for GFP was detected.
Regarding the TNAP-Cre mouse model the AF was collected from fetuses obtained
from mating TNAP-Cre males with different females (Z/Red or Z/eGFP, in which
there is the expression of lacZ before Cre-mediated excision and the Red or
enhanced GFP genes after Cre excision; or Tomato in which after Cre-mediated ex-
cision there is only the Tomato expression), and analyzed at two embryonic stages
(E10.5 and E13). Unfortunately TNAP-Cre mouse model turned out not specific for
the purpose, because the fluorescence signal in the fetuses was spread in the whole
body and not present only in the PGC (Figure 16), indicating that the Cre-mediated
excision was happened in different tissues.
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Figure 16: TNAP expression. (a,b) A whole-mount E8.5 double transgenic (TNAP-Cre-
Tomato) embryo showing the Tomato signal in the whole body (c,d) A whole-mount E13 dou-
ble transgenic (TNAP-Cre-Z/Red) embryos showing the Red signal in the whole body. Here
there is also the comparison with a wild type embryo (e,f,g,h) A whole-mount E10.5 and E13
double transgenic (TNAP-Cre-Z/eGFP) embryos showing the GFP signal in the whole body. 
Results obtained from these experiments told us that mouse AFS cells cannot be re-
programmed in vitro like PGCs did, and they don't express Oct4. 
59
4. Induction of pluripotency of mouse AFS cells
To explore the reprogramming of mouse AFS cells a protocol that involve the use of
a non-viral method, the PB system, has been established. PB transposition is host-
factor independent, and has recently been demonstrated to be functional in various
human and mouse cell lines [176,177,178,179]. The PB transposon/transposase sys-
tem requires only the inverted terminal repeats flanking a transgene and transient ex-
pression of the transposase enzyme to catalyse insertion or excision events [180].
For the induction to the pluripotency the four Yamanaka's factors (Oct4, Klf4, c-Myc
and Sox2) have been used, they were toghether in an ORFs linked with 2A peptide
sequences into the PB-TET transposon plasmid (called PB-TET-OKMS), under the
transcriptional control of the tetO2 tetracycline/doxycycline inducible promoter. All
were linked to the gene of a cherry fluorescent protein through an IRES sequence, to
allow monitoring the tightness of doxycycline regulation and later demonstration of
the reprogrammed cells capacity for exogenous-factor-independent maintenance.
The reverse tetracycline transactivator (rtTA) protein, necessary for the activation of
the expression control by doxycycline, was provided also by another transposon
plasmid. AF were collected from fetuses obtained from Oct4-GFP mice, used to mon-
itor the expression of the endogenous Oct4 in reprogrammed cells. Mouse AFS were
transfected with circular PB-TET-OKMS and rtTA plasmids in conjunction with the PB
transposase expression plasmid (mPBase). In two separate experiments, performed
according to the protocol described in figure 17, mouse AFS cells culture were trans-
fected with Oct4, Klf4, c-Myc and Sox2. Mouse AFS underwent ES-cell-like colony
formation, which resulted in the derivation of self-renewing cell lines displaying key
characteristics of reprogramming.
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Figure 17: Reprogramming protocol of mouse AFS cells. Mouse AFS cells were plated on
a feeder layer of mitotically inactivated MEF in ES medium, and transfected using fugene
(day 0) with PB-TET-OKMS, PB-rtTA and mPBase. Expression of 4 factors was achieved by
adding doxycycline in culture (day 1), 24 hours after the transfection. Colonies emerged 20
days post-transfection and they were picked on day 30 and transferred to feeder layers in ES
Medium with/without doxycycline. 
The first colonies appeared 20 days after doxycycline induction, and they were
picked after 30 days. The standard concentration for the doxocyclyne was 1.5 ug/ml,
as previously described [120]. Around twenty PB-TET-OKMS-induced colonies were
picked from mouse AFS induction fields and passaged on inactivated fibroblast feed-
er layers. Surviving clones were maintained in doxycycline during establishment, until
found to be doxycycline independent in replicate wells as it is shown in figure 18. The
clones tested passed the alkaline phosphatase staining criterion, and they were posi-
tive for the cell-surface marker SSEA1 and nuclear-localized Nanog protein (Figure
19).
61
Figure 18: Detection of the exogenous factors and endogenous Oct4 in reprogrammed
clone. PB-TET-reprogrammed clones were screened for cherry and Oct4 expression to de-
termine general transgene activity in the presence and absence of doxycycline. Scale bar=
100um.
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Figure 19: Cell lines generated by PB-mediated factor transposition. Stable doxycycline-
independent cell lines activate alkaline phosphatase (AP), SSEA1 and Nanog. Scale bars,
100um.
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VII. Discussion
Experiments accomplished in this thesis have confirmed that a population of c-kit+
cells is present in the mouse amniotic fluid, like described also in [64] and [62], and
their number change during the course of gestation. A slight difference regarding the
number of c-kit+ cells present in the amniotic fluid has been highlited between this
data and data obtained from [64], this probably was due to the different lineage de-
pletion cocktail of antibodies used; in Ditadi at al., it was consistituted from: CD3,
CD4, CD8, CD19, B220, Gr1, Mac1, Ter119, and NK1.1, while the one used here
was composed from: CD5, CD45R(B220), CD11b, Anti-Gr1 (Ly-6G/C), 7-4 (Ly-6B),
Ter119. Flow cytometer analysis have highlighetd that mouse AFS cells expressed
markers of mesenchymal stem cells (CD90, CD105), hematopietic cells (CD45,
CD34, Sca1) and also endothelial cells (Flk1, CD31). Two distinct populations have
been detected in the amniotic fluid, ditsinguishable for the intensity of expression of
the marker c-kit, for this reason they were called c-kithigh and c-kitlow. They differed
also for the expression of some other evaluated markers, in fact c-kithigh expressed
only CD45, CD90 and CD44 while c-kitlow expressed all the markers analyzed. Their
hematopietic potential has been studied, but no differences showed up, in fact under
appropriate differentiation conditions c-kithigh and c-kitlow were able to generate all the
blood lineages (ie, myeloid and erythroid colonies). In vitro experiments didn't high-
light differences between the two populations, so in vivo experiments will be neces-
sary to evaluate their potential.
Mouse AFS cells were analyzed for the gene expression of the pluripotency markers
c-Myc, Klf4, Oct4, Sox2 and Nanog at population level and also in single cells PCR.
Quantitative Real Time PCR at populations level revealed that expression was very
low if compare with expression of the same gene of mouse ES cells. There were no
expression for the genes Nanog and Sox2 (at E11.5). Genes expressed at higher
levels than mouse ES cells were c-Myc and Klf4 at E11.5. For a more detailed analy-
sis a single cells PCR was done at different embryonic stages (10.5-14.5). It has
been found that in almost all the embyonic stages evaluated there were cells that co-
expressed Sox-2 and c-Myc (sm), Klf4 and c-Myc (km). Besided at the embryonic
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stages 12.5 and 13.5 different cells were found to co-express more pluripotency
markers (see table 2), and the embryonic stage 13.5 was the only one in which there
were 5% of cells that co-express three relevant pluripotency marker (Klf4, Oct4 and
Sox2). The novelty and the surplus value of the single cell approach in respect to
populations analysis is represented by the fact that with this technique it is evaluated
not only the expression of each considered gene, but also the co-expression of more
genes in the same cell, that is closely related to the biological activity and the differ-
entiation capacity of that cell. These data confirmed cellular heterogeneity of mouse
AFS cells and suggest that at E13.5 cells are closer to mouse ES cells.
Results obtained after the injection of mouse AFS cells into the mouse model of
SMA, HSA-Cre SmnF7/F7 suggest that they have a therapeutic effect, similar to mouse
BM cells, when compared one month after the transplantation. However relevant dif-
ferences have been identified in a long term period, in fact 15 month post transplata-
tion BM-treated displayed a high number of central nucleated fibers (39.90% ±
17.68%) and consistent infiltration of interstitial tissue between the myofibers, a situa-
tion that differed greatly from the one observed in AFS-treated mice. Moreover, at
this stage (15 months pt), no GFP+ fibers were found in BM-treated animals. This
finding highlights the sustained effect of AFS cells transplantation. These long-term
effect suggest that mouse AFS cells, differently to mouse BM cells, could integrate
into the muscle stem cells niche, but more experiment will needed to evaluate the hy-
pothesis. Expanded AFS cells intravenously injected demonstrated the maintenance
of the cells’s regenerative properties after culture. Twenty percent of the fibers was of
donor origin, a remarkable result, given that (a) some adult stem and progenitor cells
have proven difficult to expand in culture and (b) skeletal muscle SCs multiply rapidly
in culture but show diminished regenerative capacity when transplanted in vivo [174].
Nevertheless, 20% was lower than the value achieved in animals having received
freshly isolated cells. Further work is required to assess the relationship between
myogenic potential and expansion conditions.
Potential sources of AFS cells in the developing fetus are diverse [181]. CD117 (c-
Kit), the surface marker used for immunoselection of AFS cells, plays an important
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role in gametogenesis, melanogenesis and hematopoiesis [182,183]. This knowledge
together with the recent demonstration that human AFS cells, obtained from first and
mid trimester, can be reprogrammed to pluripotency in vitro, without the need to force
the expression of Yamanaka's factor, but only if stimulated with VPA [71,72], sug-
gested the idea that AFS cells could be PGC. PGC are not pluripotent, but they can
achieved pluripotency in vitro, and became EG cells, if stimulated with particular cy-
tokines. To sustain this hypothesis it has been observed that during the mouse em-
bryonic development, the migration of PGCs is time-correlated with the formation of
the amnion [167]. Mouse AFS cells have been cultivated following the protocol used
to reprogramm PGC into EG cells [28,31]. Mouse AFS cells did not form EG cells,
while single cells obtained from GRs, reprogrammed under the same condition. Two
mouse models have been used for investigation of this idea: Oct4-GFP and TNAP-
Cre. Lomeli H at al., evaluated the in vivo specificity of excision achieved by the
TNAP-Cre mouse lines by crossing them with the double-reporter line, Z/AP. The Z/
AP transgene expresses lacZ before Cre-mediated excision and the heat-resistant
human alkaline phosphatase (hAP) gene after Cre excision. Double transgenic
TNAP-Cre/Z/AP embryos showed the initial hAP activity was specific to the PGCs at
E10.5. After midgestation, however, it was also expressed in the labyrinthine region
of the placenta, the intestine and the neural tube. A detailed analysis of E13 embryos
from crosses between TNAP-Cre males and Z/AP females showed 8 out of 16 em-
bryos were positive exclusively in PGCs. [184] The same TNAP-Cre mouse line has
been crossed with different report lines: Z/eGFP, Z/Red and Tomato. All the double-
transegnic embryos analized showed a Cre exicision not restricted to PGC,for this
reason no conclusion can be obtained from the use of the TNAP-Cre line, as it
showed up to be unspecific (see figure 16). The analysis of the Oct4-GFP mice
demonstrated that no Oct4 positive cells were present in the AF. The results from the
reprogramming experiments, together with the ones obtained from the Oct4-GFP line
tell us that mouse AFS cells are not PGC. However it is important to remind that
Oct4-GFP mice are not lineage tracking model, so if mouse AFS cells, during the em-
bryo development, go through the germ cells lineage it is still unknown. More experi-
ments will be necessary to answer at the origin question and probably it will be nec-
essary to investigate not only the germ cells origin hypothesis.
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Since their discovery in 2006 the iPS cells have opened great expectation for the
treatment and study of diseases. So far in different works they have been used in
mice for the treatment of some disease, like for example hemophilia A [134] and
sickle cell anemia [133]. iPS cells have also been established from patients with
adenosine deaminase deficiency, Schwachman-Bodian-Diamond syndrome, Gauch-
er disease, Duchenne and Becker muscular dystrophy, Parkinson disease, Hunting-
ton disease, type 1 diabetes mellitus, Down syndrome, Lesch-Nyhan syndrome,
amyotrophic lateral sclerosis, spinal muscular atrophy, and Fanconi anemia
[118,135,136,137,138]. The recent finding regarding the low immunogenicity of trans-
planted cells differentiated from iPSCs [185] make them a more promising research
tool. Considering all the congenital diseases that can be detected in the fetus through
the prenatal diagnosis, cells obtained from the amniotic fluid can be a good source to
obtain iPS that could be used both for the treatment and the study of the disease.
The method used to obtain the induction of pluripotency is relevant for their safety.
The PB system is a non-viral method suitable for the reprogramming, it allow the
production of xeno-free iPS cells contrary to current viral production protocols that
use xenobiotic conditions. The accurate transgene removal through transposase ex-
pression has been demonstrated in various cell lines [178,179,180]. Here we have
showed that the PB system is a suitable method for the reprogramming of mouse
AFS cells. These are only preliminary results and more experiments will be neces-
sary for complete the characterisation of the cells. The next step will be to use the
same protocol used here to obtain iPS from human AFS cells obtained from healthy
and diseased fetuses.
The "perfect" cell source for regenerative medicine should be derived from ethically
acceptable sources, should have the potential to be maintained in culture indefinitely,
should be inducible to differentiate into mature cell from all the tissues, and should be
safe. Several cells type have been studied that might respond (totally or in part) to
those requirements. In theory, a bank of 100.000 amniotic fluid specimens could po-
tentially supply 99% of the US population with a perfect match for transplantation [42]
thus making AFS a truly promising source of cells for regenerative medicine
therapies.
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